Barclays upgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Underweight to Equalweight with a price target of $24.00 (from $9.00).Following the announcement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE